This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Robert Epstein, M.D., M.S. to its Board of Directors, and that Ronald A. DePinho, M.D. will retire from the AVEO Board effective December 31, 2012. Dr. DePinho co-founded AVEO and has served as a member of the Board for more than 11 years. In September 2011, he was appointed as the fourth full-time president of the University of Texas MD Anderson Cancer Center.
“On behalf of the AVEO team, I want to express our deep gratitude and appreciation to Dr. DePinho for his role in founding the company which was based on his scientific concept of tumor maintenance, a paradigm which fueled our internal drug discovery pipeline and formed the basis for our Human Response Platform™ designed to enable more accurate clinical testing of cancer drugs,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO Oncology. “His profound focus on improving the lives of cancer patients, as well as his years of dedication and counsel as a Board member, will continue to inspire us at AVEO.”
Mr. Ha-Ngoc continued, “Based on his years of experience at Medco, Dr. Epstein brings important insights into the payor perspective and deep expertise in health economics to our Board as we prepare for the potential launch of tivozanib. In addition, Dr. Epstein’s experience leading personalized medicine initiatives at Medco will add value as we continue to expand tivozanib clinical development beyond RCC through biomarker trials in colorectal and breast cancers.”
Dr. Epstein was most recently president of the Medco-UBC Division and chief R&D officer of Medco Health Solutions, Inc. In this role, Dr. Epstein was responsible for launching Medco’s personalized medicine research and programs as well as the Medco Research Consortium, and oversaw all of Medco's research initiatives in personalized medicine, drug safety, health economics, outcomes, and comparative effectiveness conducted by more than 1,800 researchers worldwide. Dr. Epstein previously served as Medco’s senior vice president and chief medical officer for 13 years. Before joining the private sector, Dr. Epstein was an epidemiologist and held various positions in public health and academia. He is the former president of the International Society of Pharmacoeconomics and Outcomes Research, and has served on the Board of Directors of the Drug Information Association. In 2008, he was elected to the CDC EGAPP Stakeholder Committee and the AHRQ CERT Steering Committee. He has published more than 50 peer-reviewed medical articles and book chapters, and serves as a reviewer for several influential medical journals.